JNJ

#20
Johnson & Johnson Common Stock
227.8 1 USD
-1.33%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
227.72
231.48
Rango anual
149.04
251.71
Cambio diario
-1.33%
Variación mensual
-0.05%
Variación en los últimos 6 meses
+10.45%
Cambio anual
+48.02%
Cierres anteriores
230.8 7
Open
230.8 8
Mínimo
227.7 2
High
231.4 8
Volumen
682
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 548.39 B
  • Employee 141 K
  • Founded N/A
  • CEO Joaquin Duato
  • Website www.jnj.com
  • Headquarter New Jersey, United States
  • FIGI BBG000BMHYD1
  • Industry Fabricantes de medicamentos — general
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
18.82
Relación precio/flujo de caja
5.35
Dividendos por acción
5.14
Rendimiento por dividendo, %
2.48

Johnson & Johnson Common Stock

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments. The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.

Noticias